Tildacerfont
SPR001-210
Phase 2 small_molecule terminated
Quick answer
Tildacerfont for Polycystic Ovary Syndrome is a Phase 2 program (small_molecule) at SPRUCE BIOSCIENCES, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- SPRUCE BIOSCIENCES, INC.
- Indication
- Polycystic Ovary Syndrome
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated